首页> 外文期刊>Stem Cell Research & Therapy >Arterial endothelium creates a permissive niche for expansion of human cord blood hematopoietic stem and progenitor cells
【24h】

Arterial endothelium creates a permissive niche for expansion of human cord blood hematopoietic stem and progenitor cells

机译:动脉内皮为人脐血造血干和祖细胞产生允许的利基。

获取原文
           

摘要

Although cord blood (CB) offers promise for treatment of patients with high-risk hematological malignancies and immune disorders, the limited numbers of hematopoietic stem cell (HSC)/progenitor cell in a CB unit and straitened circumstances in expanding ex vivo make it quite challenging to develop the successful cell therapies. In this study, a novel strategy has been developed to support ex vivo expansion of hematopoietic stem and progenitor cells (HSPCs) by coculture with engineered human umbilical arterial endothelial cells (HuAECs-E4orf1-GFP), which expresses E4ORF1 stably by using a retroviral system. Coculture of CD34 hCB cells with HuAECs-E4orf1-GFP resulted in generation of considerably more total nucleated cells, CD34 CD38?, and CD34 CD38?CD90 HSPCs in comparison with that of cytokines alone or that of coculture with human umbilical vein endothelial cells (HuVECs) after 14-day amplification. The in vitro multilineage differentiation potential and in vivo repopulating capacity of the expanded hematopoietic cells cocultured with HuAECs-E4orf1-GFP were also markedly enhanced compared with the other two control groups. DLL4, a major determinant of arterial endothelial cell (EC) identity, was associated with CD34 hCB cells amplified on HuAECs-E4orf1-GFP. Collectively, we demonstrated that HuAECs acted as a permissive niche in facilitating expansion of HSPCs. Our study further implicated that the crucial factors and related pathways presented in HuAECs may give a hint to maintain self-renewal of bona fide HSCs.
机译:虽然脐带血(CB)提供了治疗高危血液恶性肿瘤和免疫紊乱的患者的承诺,但CB单位的有限造血干细胞(HSC)/祖细胞和扩展前的危机情况使其变得非常具有挑战性发展成功的细胞疗法。在这项研究中,已经开发了一种新的策略,通过通过使用逆转录病毒系统稳定地表达E4ORF1,通过与工程化的人脐动脉内皮细胞(HUAECS-E4ORF1-GFP)来支持造血干细胞和祖细胞(HSPC)的前体内扩张。 。与Huaecs-E4ORF1-GFP的CD34 HCB细胞的共培养导致相当多的总成核细胞,CD34 CD38-,和CD34 CD38?CD90 HSPCs与单独的细胞因子或与人脐静脉内皮细胞的共培养(Huvecs)相比)14天扩增后。与其他两种对照组相比,共有与Huaecs-E4ORF1-GFP的扩张造血细胞的体外多线性分化电位和体内重新扣除能力也明显增强。 DLL4是动脉内皮细胞(EC)同一性的主要决定因素与在Huaecs-E4ORF1-GFP上扩增的CD34 HCB细胞相关。集体,我们展示了Huaecs作为促进Hspcs扩张的允许利基。我们的研究进一步涉及Huaecs中提出的关键因素和相关途径可能会提示维持真正的富士·富人HSC的自我更新。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号